GET DAILY SIGNALSIMMP: Assessing the Path to a +20% Move Toward the $4.00 Target
Key Takeaways
- The central target used here is $4.00, a technical and psychological recovery objective — not an analyst consensus — representing roughly 20% upside from the latest close of $3.34.
- Immutep Limited (IMMP) lacks a reliable multi-analyst price-target aggregate, because coverage collapsed after the March 2026 TACTI-004 trial failure and targets are distorted by a 1-for-20 reverse split of its ADSs (American Depositary Shares).
- The only current sell-side figure is a single Buy from Maxim Group whose split-adjusted $30 figure is an outlier, not a credible consensus.
- The strongest supporting factors are a cash balance near $68.9 million, minimal debt, and a broadened pipeline including positive Phase I data for IMP761.
- The biggest risks are the discontinued Phase III TACTI-004 lung cancer trial, pending securities class actions, a recent Nasdaq delisting battle, and persistent operating losses.
- Readers can dig deeper into the ticker's Major News, Today's Price Move, Forecast, and Earnings pages for ongoing updates.
- For automated trade ideas across thousands of stocks and ETFs, explore Trending AI Robots.
How the $4.00 Target Was Established
Immutep Limited (IMMP) is an Australian clinical-stage immunotherapy company whose ADSs trade on Nasdaq under IMMP. It is a pioneer in LAG-3 (Lymphocyte Activation Gene-3) biology, developing therapies that either stimulate the immune system against cancer or suppress it in autoimmune disease. Unlike a typical large-cap, IMMP does not have a clean, current analyst consensus.
After the company's TACTI-004 Phase III trial of its lead asset eftilagimod alfa (efti) in first-line non-small cell lung cancer was discontinued for futility on March 13, 2026, the ADS fell roughly 83% in a single session, and most coverage was downgraded or withdrawn. In September 2026 the company completed a 1-for-20 reverse split of its ADSs (changing the ratio from one ADS per 10 ordinary shares to one per 200), which makes older price targets difficult to compare directly.
What remains is thin: a single Buy from Maxim Group, whose pre-split $1.50 target appears as a mechanically split-adjusted $30 in some quote feeds — an outlier that is not a usable consensus. Because no meaningful multi-analyst aggregate exists, the $4.00 central target used here is a fallback, drawn from technical and public-discussion context: a round-number resistance level roughly 20% above the latest close, just above the stock's post-split intraday high near $3.49. It is a directional objective, not a published price forecast. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
The ADS closed at $3.34 on November 6, 2026, giving the company a market capitalization of only about $24.6 million. Reaching $4.00 would require a move of about $0.66, or roughly 20% — a modest move in percentage terms, but one that would have to be driven almost entirely by sentiment and pipeline news, because IMMP is pre-commercial and generates revenue mainly from grants, R&D tax incentives, and interest rather than product sales.
The company's path runs through its remaining clinical programs. Management has said it intends to focus registration-directed development of efti on head and neck squamous cell carcinoma (HNSCC) in patients with low PD-L1 (CPS <1) and on the neoadjuvant soft tissue sarcoma setting, with new trials targeted to start in the second half of calendar 2027. Meanwhile, IMP761, an agonist LAG-3 antibody for autoimmune disease, delivered positive Phase I data showing statistically significant, exposure-dependent inhibition of T-cell-driven immune responses. These readouts, rather than near-term earnings, are what would need to re-rate the shares.
What Could Support a Move Toward the Target
- Balance sheet: total cash near $68.9 million against minimal debt gives the company runway to advance its pipeline without immediate dilution pressure.
- Pipeline breadth: IMP761's early immunology data and the refocused efti strategy offer multiple shots on goal beyond the failed lung cancer program.
- Partnerships: collaborations with Merck (whose pembrolizumab is used in efti combination studies), Novartis, EOC Pharma, and Dr Reddy's provide validation and potential milestone economics.
- Listing stability: regaining Nasdaq minimum bid compliance in October 2026 removes an acute overhang on the ADS.
What Could Prevent the Target From Being Reached
- Clinical risk: the TACTI-004 futility outcome undercuts confidence in efti's core thesis and forces a costly pivot that may take years to prove out.
- Litigation: securities class actions allege the company misled investors about TACTI-004's prospects, a risk to both capital and management attention.
- Financial drain: the company posts persistent net losses and remains dependent on grants and incentives for revenue.
- Market structure: a sub-$25 million market cap, very low average volume, and a recent reverse split make the ADS prone to sharp, sentiment-driven swings in both directions.
Technical Levels and Market Structure
Following the reverse split, the ADS has traded in a range roughly between $2.66 and $3.49, with the $3.49 area acting as near-term resistance. A move toward $4.00 would require clearing that level and the $4.00 round-number zone, which could then become a fresh support area if reclaimed. Below, the $3.00–$2.66 band represents the primary support zone established since the September 2026 split.
Time Horizon and What Investors Should Monitor
With no credible multi-analyst 12-month consensus available, the $4.00 objective carries no firm time horizon. Investors should monitor the initiation and enrollment of the refocused efti registration studies, further IMP761 data, cash runway updates, quarterly activities reports, any resolution or escalation of the class action litigation, and continued Nasdaq listing compliance. Clinical and regulatory news, rather than earnings, will drive the stock.
Using AI Daily Buy/Sell Signals in My Research
For investors who want a systematic way to track developments like these, Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. In my own process, I rely on these signals to spot shifting trends more efficiently than scanning charts manually, and they serve as a useful complement to fundamental research on names like IMMP.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
IMMP's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for IMMP turned positive on October 20, 2026. Looking at past instances where IMMP's MACD turned positive, the stock continued to rise in 35 of 40 cases over the following month. The odds of a continued upward trend are 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where IMMP's RSI Indicator exited the oversold zone, 22 of 26 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on IMMP as a result. In 69 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
Following a +6.67% 3-day Advance, the price is estimated to grow further. Considering data from situations where IMMP advanced for three days, in 211 of 254 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
IMMP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMMP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for IMMP entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 18 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 78 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.999) is normal, around the industry mean (3.498). P/E Ratio (-0.310) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (4.627) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 89 (best 1 - 100 worst), indicating slightly worse than average price growth. IMMP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMMP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of anti-cancer therapeutics
Industry Biotechnology
Advertisement